PIK3CA-Related Overgrowth Spectrum (PROS)

DBCOND0076518Congenital, Hereditary, and Neonatal Diseases and AbnormalitiesMusculoskeletal and Connective Tissue Diseases

PIK3CA-Related Overgrowth Spectrum (PROS) is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as
PIK3CA Related Overgrowth Spectrum · PIK3CA-related Overgrowth Spectrum
Classified under
Indicated drugs

Resolves to

Vocabularies
SNOMED CT737037004MedDRA10081236UMLSC4728213

What you can answer from here — as of October 25, 2026

1Indicated drugWith each drug's targets and mechanism
Listed above
1Structured indicationPopulation, line of therapy, route and combination as fields, not prose
Sign in
14Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which approved drugs for PIK3CA-Related Overgrowth Spectrum (PROS) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In